Freenome, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FRNM research report →
Range $17 – $21
Price Chart
About the company
Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome's first commercial-stage test, SimpleScreen CRC for colorectal cancer, is under review by the U.
- CEO
- Aaron Elliott
- IPO
- 2026
- Employees
- 378
- HQ
- Brisbane, CA, US
Get TickerSpark's AI analysis on FRNM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $76.35M
- P/E
- -2.39
- PEG
- 0.02
- P/S
- 0.37
- P/B
- 0.55
- EV/EBITDA
- -1.44
- Div Yield
- 0.00%
- Gross Margin
- 47.79%
- Op Margin
- -43.80%
- Net Margin
- -50.83%
- ROE
- -60.34%
- ROIC
- -13.46%
Latest fiscal year · YoY change
- Revenue
- $30.41M+0.0%
- Gross Profit
- $-168,652,000+0.0%
- Op Income
- $-223,469,000
- Net Income
- $-219,343,000+0.0%
- EPS
- $-8.28+0.0%
- OCF Growth
- +0.0%
- FCF Growth
- +0.0%
- 52W High
- $17.50
- 52W Low
- $9.28
- 50D MA
- $13.50
- 200D MA
- $12.29
- Beta
- 0.35
- RSI (14)
- 34
- Avg Volume
- 835.42K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Freenome’s first public-company quarter was dominated by a large Abbott milestone-driven revenue surge, while management emphasized early commercial launch work for SimpleScreen CRC and Lung and a pipeline of additional readouts ahead.· November 10, 2026
- Q3 revenue was $183.5 million, driven mainly by $180 million recognized from the Abbott agreement after FDA approval of SimpleScreen CRC.
- Net income was $60.1 million, or $0.58 per share, versus a $64.5 million net loss a year ago; adjusted EBITDA was $117.9 million.
- SimpleScreen CRC launched with Abbott on September 30; management said it is too early for volume guidance, but more than 2,000 clinical sites requested kits and EMR integrations are starting to go live.
- The company highlighted SimpleScreen CRC version 2 improvements and plans to file a supplemental PMA by year-end, with FDA approval expected in the second half of 2027.
- SimpleScreen Lung has launched as an LDT, with top-line data showing 85% sensitivity at 50% specificity and 99.8% negative predictive value, while enrollment continues for the registrational PROACT Lung study.
Total revenue in Q3 2026 was $183.5 million, up from $1 million in Q3 2025. License and collaboration revenue was $182.5 million, including $180 million recognized under the Abbott collaboration after FDA approval of SimpleScreen CRC; service and other revenue was $0.9 million. Cost of service was $0.5 million versus $0.6 million a year ago. Operating expenses were $113 million versus $65.7 million last year, with R&D at $68.4 million and G&A at $44.6 million. Operating income was $70 million versus an operating loss of $65.3 million; net income was $60.1 million, or $0.58 per share, versus a net loss of $64.5 million, or $0.95 per share. Adjusted EBITDA was $117.9 million versus -$56.3 million, and free cash flow was $35.7 million versus -$44.8 million. The company ended the quarter with approximately $430 million in cash, cash equivalents, and marketable securities and said current cash is expected to fund operations into 2028. For Q4 2026, revenue guidance is $2 million-$4 million, implying full-year revenue of $192 million-$194 million; management said they do not expect meaningful testing revenue or royalties in Q4.
Aaron Elliott framed the quarter as the start of Freenome’s public-market story and focused on building a commercial footprint around AI-enabled cancer screening. He emphasized the company’s strategy of pairing Abbott’s primary-care reach with Freenome’s own health-system channel, saying the goal is to convert the large unscreened population and build a long-term data flywheel. His tone was upbeat but cautious on near-term launch metrics, repeatedly noting that the CRC launch is still early and that 2027 is when commercial traction should become clearer.
Linh Le highlighted the financial impact of the Abbott milestone, which drove the quarter’s $183.5 million of revenue and the $60.1 million net profit. She broke out the $180 million recognized under the collaboration, including $157.5 million for the exclusive commercialization license and a $22.5 million cumulative catch-up adjustment, and noted that the quarter also included $9.9 million of stock-based comp in R&D and $29.8 million in G&A tied to restrictive stock awards. She said the balance sheet ended with about $430 million in cash, cash equivalents, and marketable securities, and reiterated that the company expects its current resources to fund operations into 2028; Q4 revenue guidance was set at $2 million-$4 million, with lab service fees described as gross-margin neutral.
Analysts focused on how quickly Abbott’s CRC launch can translate into meaningful volume, with questions about rep deployment, payer coverage, EMR integrations, and whether blood testing is used only after stool-based options are declined. Management said Abbott’s 800-person sales force is trained, roughly 2,000 clinical sites have requested kits, EMR integrations should start going live in November, and the team expects to be able to discuss more meaningful commercial success over the next couple of quarters. On pricing and royalties, Aaron Elliott said there is no timing expectation yet for royalties, that Abbott controls ASP and Medicare coding strategy, and that Freenome will revisit coding with the V2 test and potentially ADLT. Questions on the lung launch and future pipeline centered on why the protein-only assay launched first, when V2 and the next readouts will arrive, and how the company thinks about attach rates; management said the protein-only launch was driven by cost and pricing flexibility, the next two single-cancer readouts are due in December with launches in the first half of 2027, and the MCED readout is expected in Q2 2027 with launch in the back half of 2027.
The call showed that Freenome already monetized a major regulatory and commercial milestone, and management believes the Abbott relationship can scale screening adoption while preserving long-term economics through royalties and multi-test attach potential. The company also pointed to concrete pipeline progress: an improved CRC version, a launched lung test, two more single-cancer readouts due in December, and an MCED readout later in 2027.
Near-term operating data remain sparse because the CRC launch is still only about a month old, and management offered no volume guidance or near-term royalty timing. Several key value drivers are still pending, including payer coverage expansion, EMR integration, V2 FDA approval, and future pipeline readouts, and the company acknowledged that meaningful commercial traction is not expected until 2027 and beyond.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- —
- Shares Outstanding
- 8.16M
- Float Shares
- 7.12M
of shares held by institutions
4 13F filers
Buy/sell ratio 2.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 923.17K | ▲ 923.17K |
| Marshall Wace, Llp | 346.29K | ▲ 346.29K |
| Morgan Stanley | 179.59K | ▲ 179.59K |
Held by 36 ETFs
Biggest fund positions in FRNM by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 2, 26 | Elliott Aaron Matthew | other | 71,920 |
| Jul 20, 26 | Waksal Harlan | other | 30,000 |
| Jul 20, 26 | Waksal Harlan | other | 30,000 |
| Jul 20, 26 | Nuechterlein Carole | other | 0 |
| Jul 20, 26 | Costello Ann Catherine | other | 0 |
| Jul 20, 26 | VAN OORT DOUGLAS M | other | 0 |
| Jul 20, 26 | VAN OORT DOUGLAS M | other | 0 |
| Jul 20, 26 | VAN OORT DOUGLAS M | other | 0 |
| Jul 20, 26 | VAN OORT DOUGLAS M | other | 0 |
| Jul 20, 26 | Elliott Aaron Matthew | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our FRNM coverage
Recent articles, reports, and earnings notes.
Want a deeper read on FRNM?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Freenome to Participate in the Piper Sandler 38th Annual Healthcare Conference
globenewswire.com · Nov 17
Freenome (NASDAQ:FRNM) Stock Has Average Target Price of $18.00 According to Analysts
defenseworld.net · Nov 11
Freenome Q3 Earnings Call Highlights
marketbeat.com · Nov 10
Freenome Reports Third Quarter 2026 Financial Results
globenewswire.com · Nov 10
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
fool.com · Oct 20
Freenome Expands Personalized Cancer Detection Portfolio, Launching SimpleScreen™ Lung Test With FDA-Approved SimpleScreen CRC Option
globenewswire.com · Oct 20
Freenome to Report Third Quarter 2026 Financial Results on November 10, 2026
globenewswire.com · Oct 15
Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026
globenewswire.com · Oct 11
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
